At 9.6% CAGR, Middle East & Africa Therapeutic Vaccines Market is Projected to be Worth US$ 4,471.70 Thousand by 2031, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa therapeutic vaccines market was valued at US$ 2,358.36 thousand in 2024 and is expected to reach US$ 4,471.70 thousand by 2031, registering a CAGR of 9.6% from 2024 to 2031. Rising prevalence of chronic conditions and extending product pipeline are among the critical factors attributed to drive the Middle East & Africa therapeutic vaccines market.

Chronic conditions such as cancer, neurological diseases, and autoimmune diseases are becoming more widespread globally due to factors such as aging, lifestyle changes, and environmental influence. According to the World Health Organization's (WHO) Noncommunicable Diseases Factsheet 2023, these diseases account for 41 thousand global deaths annually, equivalent to 74% of total mortality. Per the Global Cancer Facts & Figures, ~20 thousand cancer cases were diagnosed in 2022, and 9.7 thousand people died from the disease in the same year. Moreover, as per a study titled "Global, regional, and national burden of disorders affecting the nervous system, 1990-2021," released by The Lancet Neurology in April 2024, more than 3 billion people (43% of the world's population) were living with a neurological condition worldwide in 2021. According to an article titled "The Global Landscape of Autoimmune Disease," published in February 2024, autoimmune diseases affect 5-10% of the industrial world population. In addition, as per the WHO multiple sclerosis factsheet, over 1.8 thousand people suffered from multiple sclerosis worldwide as of August 2023.

Thus, the surging incidences of various chronic conditions highlight the urgent need for innovative therapeutic interventions. Therapeutic vaccines are designed to treat existing diseases instead of preventing their onset. These vaccines aim to stimulate the body's immune system to target and treat specific diseases. In cancer treatment, the Sipuleucel-T (Provenge) vaccine has demonstrated the potential to improve survival rates in prostate cancer patients. Amid the elevating demand for innovative treatments for chronic diseases, therapeutic vaccines are expected to offer a new approach to long-term disease management and improve patient outcomes globally. Thus, the rising prevalence of chronic diseases fuels the therapeutic vaccines market growth.

On the contrary, regulatory challenges hampers the growth of Middle East & Africa therapeutic vaccines market.

Based on product, the Middle East & Africa therapeutic vaccines market is segmented into cancer vaccine, infectious disease vaccine, and other. The cancer vaccine segment held 100.0% market share in 2024, amassing US$ 2,358.36 thousand. It is projected to garner US$ 4,444.82 thousand by 2031 to register 9.5% CAGR during 2024-2031.

By technology, the Middle East & Africa therapeutic vaccines market is bifurcated into allogenic vaccine and autologus vaccine. The allogenic vaccines segment held 100.0% share of Middle East & Africa therapeutic vaccines market in 2024, amassing US$ 2,358.36 thousand. It is projected to garner US$ 4,450.42 thousand by 2031 to expand at 9.5% CAGR from 2024 to 2031.

In terms of end user, the Middle East & Africa therapeutic vaccines market is categorized into hospitals, clinics, and others. The hospitals segment held 62.0% share of Middle East & Africa therapeutic vaccines market in 2024, amassing US$ 1,462.64 thousand. It is projected to garner US$ 2,826.51 thousand by 2031 to expand at 9.9% CAGR from 2024 to 2031.

Based on country, the Middle East & Africa therapeutic vaccines market is categorized into the Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 42.3% share of Middle East & Africa therapeutic vaccines market in 2024. It was assessed at US$ 998.30 thousand in 2024 and is likely to hit US$ 1,996.02 thousand by 2031, registering a CAGR of 10.4% during 2024 to 2031.

Key players operating in the therapeutic vaccines market are Dendreon, BioNTech SE, Serum Institute of India Pvt. Ltd, Merck & Co Inc, Amgen Inc, ISA Pharmaceuticals BV, INOVIO Pharmaceuticals Inc, Transgene SA, THERAVECTYS SA, and CureVac SE, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com